Reversing Alzheimer's & Dementia - what does evidence say?

Yoon Hang Kim MD

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

About Dr. Kim

Dr. Yoon Hang Kim is a board-certified physician with over 20 years of experience in preventive, integrative, and functional medicine. A fellowship graduate of the University of Arizona Center for Integrative Medicine under Dr. Andrew Weil, he holds certifications in preventive medicine, medical acupuncture, and integrative and holistic medicine. His clinical work focuses on low-dose naltrexone (LDN), autoimmune conditions, chronic pain syndromes, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold-related illness. He is the author of 8 books and more than 25 peer-reviewed articles.

Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com

Important: This article is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The information presented reflects a clinician's interpretation of the current evidence and should not replace a direct evaluation by a qualified healthcare provider. Always consult your own physician before making changes to your health plan.

Can We Actually Reverse Alzheimer's Disease?

Families facing cognitive decline want to know whether diet, supplements, hormones, or a personalized treatment program can restore what has been lost.

My assessment is this: some people with cognitive impairment can improve with comprehensive treatment. However, improvement in cognition is not the same as demonstrating reversal of the underlying Alzheimer's disease process.

Dale Bredesen's ReCODE approach and the research led by Kat Toups, MD, deserve serious consideration. Their emphasis on identifying multiple contributors to cognitive decline is consistent with how I practice integrative and functional medicine. But agreement with a treatment philosophy does not establish its effectiveness — or validate every test and treatment within it.

The evidence is encouraging in some areas, preliminary in others, and sometimes overstated.

What Bredesen's Books Get Right

The End of Alzheimer's and The End of Alzheimer's Program encourage clinicians to look beyond a memory score and examine sleep, metabolic health, nutrition, medications, physical activity, and vascular disease.

That is valuable. Cognitive symptoms deserve a thorough evaluation, and patients often need sustained support to implement meaningful changes.

The strongest practical contribution may be the structure: individualized goals, coaching, care-partner involvement, and regular reassessment.

Where the books overreach is in presenting proposed mechanisms — such as inflammation, inadequate hormonal support, and toxins — as established Alzheimer's subtypes with validated treatments. These remain hypotheses and treatment-organizing categories.

A patient improving after a large treatment package does not establish which components helped or prove every proposed mechanism.

What the Clinical Research Shows

The 2022 Toups/Bredesen pilot

Twenty-five participants received nine months of personalized treatment. Mean Montreal Cognitive Assessment (MoCA) scores increased from 24.6 to 27.56, and 21 of 25 participants improved on the computerized Neurocognitive Index. [1]

These findings justify further study. However, the study lacked a randomized control group, and Alzheimer's pathology was not established through biomarker confirmation in every participant.

Practice effects, treatment of overlapping conditions, participant selection, and other influences could contribute to improvement.

The EVANTHEA randomized trial

EVANTHEA randomized 73 participants: 50 to personalized precision medicine and 23 to standard care. The latest posted version reviewed for this article was the April 20, 2026 preprint, which had not undergone peer review. [2]

The intervention produced a large reported advantage on computerized overall cognition. However, the between-group MoCA difference was not statistically significant, and MRI volume changes did not differ significantly between groups.

The study also measured Alzheimer's blood biomarkers. Their inclusion strengthens the biological characterization of participants, but the biomarker findings did not establish a significant treatment advantage demonstrating disease reversal.

Seven participants dropped out, all from the intervention group. The treatment package also prevents identification of which individual components produced benefit.

These findings warrant independent replication, longer follow-up, and careful assessment of everyday function.

The Ornish randomized trial

A 2024 trial enrolled 51 participants with mild cognitive impairment or early dementia attributed to Alzheimer's disease and evaluated a 20-week intensive lifestyle program. [9]

Several cognitive and functional outcomes favored intervention. However, the ADAS-Cog between-group result was borderline rather than statistically significant at the conventional threshold, with p = 0.053.

The study supports further investigation of intensive lifestyle treatment. It does not validate ReCODE's specific laboratory panels, hormone strategies, or supplement combinations.

U.S. POINTER

The 2025 U.S. POINTER trial included 2,111 older adults at increased risk of cognitive decline. A structured multidomain lifestyle program produced greater cognitive improvement than a self-guided program over two years. Both groups improved. [10]

The between-group advantage was approximately 0.029 standard deviations per year: statistically significant, but modest.

This is substantial evidence supporting structured lifestyle intervention in at-risk older adults. It is not evidence that established Alzheimer's dementia was reversed.

How I Interpret the Evidence

The studies address different questions. Can treating contributing conditions improve cognition? Yes, improvement is possible in selected patients. Can structured lifestyle programs support cognitive health? Randomized trials support benefit in certain populations. Does the complete ReCODE package outperform standard care? A small randomized preprint provides a preliminary signal. Which ReCODE components are necessary? Not established. Has reversal of Alzheimer's pathology been demonstrated? Not established by these studies.

Cross-trial comparisons claiming that precision medicine is several times more effective than anti-amyloid medication are also unreliable. Different populations, instruments, follow-up periods, and study designs prevent a valid direct comparison.

A Practical Integrative Cognitive Health Approach

I would describe this work as integrative cognitive health care, with clear goals and measurable outcomes.

Establish the diagnosis first

A thorough evaluation should include the patient's history and information from a family member or other knowledgeable informant.

Important questions include symptom progression, medication changes, sleep, mood, alcohol use, medical conditions, and effects on daily functioning.

Standardized cognitive assessment, appropriate laboratory testing, structural brain imaging, and formal neuropsychological testing when indicated help distinguish subjective cognitive concerns, mild cognitive impairment, and dementia.

The Alzheimer's Association DETeCD-ADRD guidance provides a structured diagnostic approach. Its Tier 1 laboratory recommendations include CBC, metabolic testing, TSH, vitamin B12, homocysteine, ESR, and CRP. [22]

Address the highest-value contributors

Nutrition: Use a sustainable Mediterranean/MIND-style dietary pattern emphasizing vegetables, legumes, nuts, unsaturated fats, and adequate protein.

Exercise: Develop an individualized program incorporating aerobic activity, strength, and balance.

Sleep: Evaluate suspected sleep apnea and treat established sleep disorders.

Cardiometabolic health: Manage hypertension, diabetes, dyslipidemia, and other vascular risks.

Nutritional deficiencies: Correct documented deficiencies and investigate their causes.

Cognitive and social engagement: Encourage meaningful learning, relationships, and activities appropriate to the person's abilities.

Implementation: Involve a care partner, establish written goals, and provide regular follow-up.

Careful assessment and sustained implementation may offer more practical value than an extensive laboratory panel without clear treatment implications.

Measure meaningful outcomes

Monitoring should include daily function, cognition, medication burden, weight, adverse effects, caregiver burden, and sustainability.

Improvement on a cognitive test matters, but so does whether the patient can manage daily activities, participate in relationships, and maintain independence.

Supplements: What the Evidence Actually Supports

No supplement discussed here has established reversal of Alzheimer's disease.

These interventions also cannot be ranked on a single efficacy scale: correcting a deficiency, slowing functional decline in dementia, and improving test performance in healthy adults are different outcomes.

Correcting B12 or folate deficiency. Appropriate when deficiency contributes to impairment. This does not establish benefit from supplementing already-adequate levels.

B vitamins for elevated homocysteine. VITACOG reported less brain atrophy in selected participants with MCI, particularly a high-homocysteine subgroup. This was an imaging finding, not proof of dementia prevention or reversal. The approximately 53% lower brain-atrophy rate applied to a subgroup with baseline homocysteine above 13 µmol/L. It does not mean a 53% reduction in Alzheimer's risk. The MRI findings also came from a subset of the 271 randomized participants. [5]

Vitamin E. TEAM-AD found slower functional decline with 2,000 IU/day in mild–moderate AD. This was preservation of daily function — approximately 19% slower decline — not memory recovery, with high-dose safety considerations. [6]

Ketogenic MCT formulation. BENEFIC reported improvements in selected cognitive measures in MCI. Findings were formulation-specific, with attrition and limited generalizability. [7]

Souvenaid/Fortasyn Connect. The 24-month LipiDiDiet primary cognitive outcome was negative. The 36-month report found less decline on some measures, with interpretation complicated by attrition and censoring. [17, 18]

Omega-3 supplements. A Cochrane review found no convincing treatment benefit in established mild–moderate AD. Nutritional indications remain separate. [8]

Curcumin. A small trial in nondemented adults reported benefits with a specific formulation. It does not establish treatment of Alzheimer's dementia. [11]

Sulforaphane. A short trial in healthy older adults reported improvements in processing speed and working memory. Alzheimer's treatment benefit remains unproven. [12]

For detailed dosing guidance and clinical protocols, visit ifmsynergy.com.

Ketogenic Diets, Hormones, and Extensive Testing

Ketogenic diets

Ketogenic interventions have preliminary evidence, but the ESPEN 2024 dementia nutrition guideline advises against their routine use to correct cognitive impairment or prevent further decline. [21]

Any individualized trial requires attention to nutritional adequacy, weight loss, medication safety, and tolerability. Strict ketosis should not become a universal requirement for cognitive care.

Hormones

The EVANTHEA intervention included hormone replacement, but the bundled design cannot establish an independent cognitive benefit from hormone treatment.

Rasgon's small randomized study examined continuation versus discontinuation of existing hormone therapy and measured cerebral glucose metabolism. It did not demonstrate Alzheimer's reversal. [16]

Its formulation findings also do not establish that all synthetic progestins negate estradiol's effects or that broad "bioidentical hormone optimization" treats dementia.

Estrogen is a steroid hormone with neuromodulatory actions; describing it simply as a neurotransmitter is imprecise.

Infection, mold, toxin, and microbiome panels

Testing should answer a specific clinical question.

The presence of an abnormal result does not establish that it caused the cognitive impairment. Likewise, improvement after treating many abnormalities simultaneously cannot validate each diagnosis or intervention.

These distinctions are especially important when extensive testing leads to costly or prolonged treatment.

Kat Toups' Contributions — and the Limits of Attribution

Toups and colleagues have contributed an uncontrolled pilot, an imaging analysis, a rationale paper, and a randomized preprint. These publications should not be counted as four independent demonstrations of treatment efficacy. [1–4]

The rationale paper discusses proposed mechanisms. The imaging publication derives from the pilot cohort.

A "remove, replace, regenerate" framework may be a useful organizing device. However, the supplied references do not verify that this is Toups' exact named framework or substantiate the detailed descriptions of her personal recovery, public statements, or current clinical workup.

Those statements require a dated primary interview, lecture, or publication before inclusion as factual attributions.

The MRI language also needs correction. The pilot's approximately 0.3% gray-matter increase was an annualized estimate from a nine-month study, compared with historical literature. It does not establish brain regeneration or better brain aging than healthy controls. [1, 3, 4]

Infections: Include the Contradictory Evidence

The herpesvirus literature illustrates why mechanistic hypotheses and observational findings must be separated from treatment evidence.

Readhead and colleagues reported molecular associations involving herpesviruses in postmortem brain tissue. That does not establish that antiviral treatment improves dementia. [13]

The Itzhaki article is a hypothesis-oriented editorial, not a controlled treatment trial. [14]

A Taiwanese retrospective cohort associated antiviral treatment in patients with clinically diagnosed HSV infection with substantially lower subsequent dementia incidence. However, observational associations do not establish causation and cannot automatically be generalized to everyone with positive HSV antibodies. [19]

The later VALAD randomized trial is essential context. Among 120 HSV-seropositive participants with early symptomatic Alzheimer's disease, valacyclovir produced greater cognitive worsening than placebo at 78 weeks. [20]

This does not settle every infection hypothesis or prevention question. It does mean that the earlier observational finding should not be presented as established evidence for antiviral treatment of Alzheimer's disease.

My Clinical Position

I support thorough evaluation, treatment of contributing conditions, structured lifestyle intervention, and individualized follow-up.

The evidence also supports clear limits on what we promise.

Some patients may improve. Some may stabilize. Others may continue to decline despite substantial effort.

A comprehensive intervention deserves evaluation as a complete package, while its individual components require their own evidence.

We can pursue meaningful improvement while remaining honest that reversal of Alzheimer's disease has not been established by these studies.

Work with Dr. Kim

If you or a family member are experiencing cognitive changes, Dr. Kim offers individualized integrative and functional medicine evaluation that complements neurologic assessment.

Learn more at www.directintegrativecare.com.

This article is educational and does not replace individualized medical evaluation.

References

1. Toups K, Hathaway A, Gordon D, et al. Precision medicine approach to Alzheimer's disease: successful pilot project. Journal of Alzheimer's Disease. 2022;88(4):1411–1421. doi:10.3233/JAD-215707
2. Toups K, Tanio CP, Hathaway A, et al. Precision medicine treatment of Alzheimer's disease: successful randomized controlled trial. Preprints. Version 3; April 20, 2026. Not peer reviewed. doi:10.20944/preprints202512.2694.v3
3. Bredesen DE, Toups K, Hathaway A, et al. Precision medicine approach to Alzheimer's disease: rationale and implications. Journal of Alzheimer's Disease. 2023;96(2):429–437. doi:10.3233/JAD-230467
4. Chwa WJ, Raji C, Toups K, et al. Longitudinal white and gray matter response to precision medicine–guided intervention for Alzheimer's disease. Journal of Alzheimer's Disease. 2023;96(3):1051–1058. doi:10.3233/JAD-230481
5. Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial (VITACOG). PLoS One. 2010;5(9):e12244. doi:10.1371/journal.pone.0012244
6. Dysken MW, Sano M, Asthana S, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014;311(1):33–44. doi:10.1001/jama.2013.282834
7. Fortier M, Castellano CA, St-Pierre V, et al. A ketogenic drink improves cognition in mild cognitive impairment: results of a 6-month RCT (BENEFIC). Alzheimer's & Dementia. 2021;17(3):543–552. doi:10.1002/alz.12206
8. Burckhardt M, Herke M, Wustmann T, Watzke S, Langer G, Fink A. Omega-3 fatty acids for the treatment of dementia. Cochrane Database of Systematic Reviews. 2016;(4):CD009002. doi:10.1002/14651858.CD009002.pub3
9. Ornish D, Madison C, Kivipelto M, et al. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled trial. Alzheimer's Research & Therapy. 2024;16:122. doi:10.1186/s13195-024-01482-z
10. Baker LD, Espeland MA, Whitmer RA, et al. Structured vs self-guided multidomain lifestyle interventions for global cognitive function: the US POINTER randomized clinical trial. JAMA. 2025;334(8):681–691. doi:10.1001/jama.2025.12923
11. Small GW, Siddarth P, Li Z, et al. Memory and brain amyloid and tau effects of a bioavailable form of curcumin in non-demented adults: a double-blind, placebo-controlled 18-month trial. American Journal of Geriatric Psychiatry. 2018;26(3):266–277. doi:10.1016/j.jagp.2017.10.010
12. Nouchi R, Hu Q, Saito T, et al. Brain training and sulforaphane intake interventions separately improve cognitive performance in healthy older adults, whereas a combination of these interventions does not have more beneficial effects: evidence from a randomized controlled trial. Nutrients. 2021;13(2):352. doi:10.3390/nu13020352
13. Readhead B, Haure-Mirande JV, Funk CC, et al. Multiscale analysis of independent Alzheimer's cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus. Neuron. 2018;99(1):64–82.e7. doi:10.1016/j.neuron.2018.05.023
14. Itzhaki RF, Lathe R, Balin BJ, et al. Microbes and Alzheimer's disease. Journal of Alzheimer's Disease. 2016;51(4):979–984. doi:10.3233/JAD-160152
15. Laukkanen T, Kunutsor S, Kauhanen J, Laukkanen JA. Sauna bathing is inversely associated with dementia and Alzheimer's disease in middle-aged Finnish men. Age and Ageing. 2017;46(2):245–249. doi:10.1093/ageing/afw212
16. Rasgon NL, Geist CL, Kenna HA, et al. Prospective randomized trial to assess effects of continuing hormone therapy on cerebral function in postmenopausal women at risk for dementia. PLoS One. 2014;9(3):e89095. doi:10.1371/journal.pone.0089095
17. Soininen H, Solomon A, Visser PJ, et al. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurology. 2017;16(12):965–975. doi:10.1016/S1474-4422(17)30332-0
18. Soininen H, Solomon A, Visser PJ, et al. 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease. Alzheimer's & Dementia. 2021;17(1):29–40. doi:10.1002/alz.12172
19. Tzeng NS, Chung CH, Lin FH, et al. Anti-herpetic medications and reduced risk of dementia in patients with herpes simplex virus infections — a nationwide, population-based cohort study in Taiwan. Neurotherapeutics. 2018;15(2):417–429. doi:10.1007/s13311-018-0611-x
20. Devanand DP, Wisniewski T, Razlighi Q, et al. Valacyclovir treatment of early symptomatic Alzheimer disease: the VALAD randomized clinical trial. JAMA. 2026;335(6):511–522. doi:10.1001/jama.2025.21738
21. Volkert D, Beck AM, Faxén-Irving G, et al. ESPEN guideline on nutrition and hydration in dementia — Update 2024. Clinical Nutrition. 2024;43(6):1599–1626. doi:10.1016/j.clnu.2024.04.039
22. Atri A, Dickerson BC, Clevenger C, et al. Alzheimer's Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer's disease and related disorders (DETeCD-ADRD): executive summary. Alzheimer's & Dementia. 2025;21(6):e14333. doi:10.1002/alz.14333

Yoon Hang Kim MD is the author of MCAS: Epidemic in Plain Sight and LDN Primer*, both available on Amazon. He is the founder of the LDN Support Group. For more clinical articles and detailed dosing guidance, visit ifmsynergy.com.*